0 comments Tuesday, December 23, 2008

We've all gotten them at one time or another: gifts of food that were disappointing or misguided, even comical. Sometimes it isn't the gift itself that doesn't work so much as the match between the gift and the recipient.

For example, I was the goofball who, with all the best of intentions, gave a Starbucks gift card to a music teacher at my daughter's school. It didn't occur to me that he might be a Mormon (see No. 7 in the list below).

Here's another example: I was once given dark chocolate as a gift, when anyone who knows me well knows that I prefer milk chocolate. (The giver in this instance happened to be my mother.)

So, with some personal experience and some tongue-in-cheek reflections on gifts from Christmases past, here is my list of 13 food gifts NOT to give:

  1. Don't give sugar-free candies or chocolates to someone with IBS (irritable bowel syndrome) or other intestinal issues. The sugar replacement often used in these products is maltitol, which is only partially digested and absorbed. The part that isn't digested tends to ferment in the intestinal tract and attract water. To someone with diarrhea -predominant IBS, having a few pieces of these sugar-free goodies can cause some "intestinal issues". (As someone who has IBS, I can speak from sad experience.) We'll leave it at that.
  2. Pay attention that you don't give tea with special properties to someone whom it might offend. The Republic of Tea, for example, makes "Get Lost" tea, described as "herb tea for weight control"; "Get it Going" tea (for regularity); and "Get Gorgeous" tea (for clear skin).
  3. Be sure you don't give alcohol to someone who doesn't (or shouldn't) drink. Even if someone has consumed alcohol in the past, they may now be avoiding it for a number of possible reasons.
  4. Don't give those tins of stale popcorn to pretty much anyone. If it isn't fresh, it isn't worth the calories.
  5. Don't give fruitcake as a food gift, because all the fruitcake jokes known to man are bound to ensue moments after it is unwrapped.
  6. Don't give a gift assortment of dark chocolates to someone who is passionate about milk chocolate (or vice versa). The same goes for giving cream-filled chocolates to someone who is wild about nuts and chews.
  7. Don't give alcohol or anything with caffeine to a member of the Church of Jesus Christ of Latter-Day Saints. These items are not in line with their beliefs.
  8. If you don't know the gift recipient all that well, avoid holiday processed meat gift packs (from gourmet catalogue companies) or other foods containing meat, in case your giftee is a vegetarian.
  9. Don't give food gifts that include chocolate, peppermint or spearmint, garlic and onions, coffee, caffeinated tea, citrus, tomato products, or chili peppers, to someone who suffers from acid reflux.
  10. Don't give any food containing pork or pork products, or that combines dairy with meat products, to someone who keeps kosher or observes Muslim dietary laws.
  11. Don't give peanut brittle, caramel apples, or candy canes to people with braces. According to H. Dixon Taylor, DDS, an orthodontist in Concord, Calif., these are the three worst food gifts for someone with orthodontics. (And about 20% of Taylor's clients happen to be grown-ups.)
  12. To that friend of yours who is working hard to lose extra pounds, don't give a gift card to The Cheesecake Factory.
  13. Don't give chocolate-covered insects to people who might be "bugged" by it. I'm serious -- this actually happened to an acquaintance's mom, and she was definitely not amused!
source WebMD

0 comments

Researchers at the University of Pennsylvania School of Medicine have discovered stem cells in the esophagus of mice that were able to grow into tissue-like structures and when placed into immune-deficient mice were able to form parts of an esophagus lining. The investigators report their findings online this month in the Journal of Clinical Investigation.

"The immediate implication is that we'll have a better understanding of the role of these stem cells in normal biology, as well as in regenerative and cancer biology," says senior author Anil K. Rustgi, MD, the T. Grier Miller Professor of Medicine and Genetics and Chief of Gastroenterology. "Down the road, we will develop a panel of markers that will define these stem cells and use them in replacement therapy for diseases like gastroesophogeal reflux disease [GERD] and also to understand Barrett's esophagus, a precursor to esophageal adenocarcinoma and how to reverse that before it becomes cancer."

Diseases of the esophagus are very common in the United States and worldwide. "Benign forms include GERD and millions are affected," notes Rustgi.

GERD can sometimes lead to inflammation of the esophagus, called esophagitis. "In some of these cases esophagitis can lead to a swapping of the normal lining of the esophagus with a lining that looks more like the intestinal lining and that's called Barrett's esophagus," explains Rustgi. "This can lead to cancer of the esophagus, which is the fastest rising cancer in the US, increasing by 7 to 8 percent a year."

The researchers set out to identify and characterize potential stem cells--those with the ability to self renew--in the esophagus to understand normal biology and how injured cells may one day be repaired.

First, they grew mouse esophageal cells they suspected were adult stem cells. Those cells formed colonies that self renewed. These cells then grew into esophageal lining tissue in a three-dimensional culture apparatus. "These tissue culture cells formed a mature epithelium sitting on top of the matrix," says Rustgi. "The whole construct is a form of tissue engineering."

The investigators then tested their pieces of esophageal lining in whole animals. When the tissue-engineered patches were transplanted under the skin of immunodeficient mice, the cells formed epithelial structures. Additionally, in a mouse model of injury of the esophagus in a normal mouse, which mimics what happens during acid reflux, green-stained stem cells migrated to the injured lining cells and co-labeled with the repaired cells, indicating involvement of the stem cells in tissue repair and regeneration.

Eventually the researchers will develop genetically engineered mouse models to be able to track molecular markers of esophageal stem cells found in a micorarray study. The group has already developed a library of human esophageal cell lines and is looking for human versions of markers already identified in mice.

"The ultimate goal is to identify esophageal stem cells in a patient, grow the patient's own stem cells, and inject them locally to replace diseased tissue with normal lining," says Rustgi.

Penn co-authors are Jiri Kalabis, Kenji Oyama, Takaomi Okawa, Hiroshi Nakagawa, Carmen Z. Michaylira, Douglas B. Stairs, and J. Alan Diehl (Department of Cancer Biology), as well as Jose-Luiz Figueiredo and Umar Mahmood from Massachusetts General Hospital, Molecular Center for Imaging Research, Boston, and Meenhard Herlyn, from The Wistar Institute, Philadelphia.

This work was funded by the National Institute of Diabetes and Digestive and Kidney Diseases and the National Cancer Institute.

This release and a related image can be found at: http://www.uphs.upenn.edu/news/News_Releases/2008/12/esophagus-tissue-growth.html

PENN Medicine is a $3.6 billion enterprise dedicated to the related missions of medical education, biomedical research, and excellence in patient care. PENN Medicine consists of the University of Pennsylvania School of Medicine (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System.

Penn's School of Medicine is currently ranked #4 in the nation in U.S.News & World Report's survey of top research-oriented medical schools; and, according to most recent data from the National Institutes of Health, received over $379 million in NIH research funds in the 2006 fiscal year. Supporting 1,700 fulltime faculty and 700 students, the School of Medicine is recognized worldwide for its superior education and training of the next generation of physician-scientists and leaders of academic medicine.

The University of Pennsylvania Health System (UPHS) includes its flagship hospital, the Hospital of the University of Pennsylvania, rated one of the nation's top ten "Honor Roll" hospitals by U.S.News & World Report; Pennsylvania Hospital, the nation's first hospital; and Penn Presbyterian Medical Center. In addition UPHS includes a primary-care provider network; a faculty practice plan; home care, hospice, and nursing home; three multispecialty satellite facilities; as well as the Penn Medicine at Rittenhouse campus, which offers comprehensive inpatient rehabilitation facilities and outpatient services in multiple specialties.

University of Pennsylvania School of Medicine
3535 Market St., Mezzanine
Philadelphia
PA 19104
United States
http:// www.med.upenn.edu

0 comments

Although irritable bowel syndrome (IBS) is the most common disease diagnosed by gastroenterologists, it's also one of the most misunderstood. That's why updated guidelines addressing the management of the condition are being released by the American College of Gastroenterology.

Through a comprehensive review of the latest medical research and expert consensus, the updated guidelines provide clinicians with a comprehensive and practical set of recommendations for the diagnosis and treatment of IBS.

"The last time the American College of Gastroenterology published guidelines for the management of IBS was in 2002, and the College recognized that in the span of five to six years there has been a remarkable explosion in knowledge that's become available that's helped us to understand the cause and management of IBS," says William Chey, M.D., professor of medicine and director of the Gastrointestinal Physiology Laboratory at the University of Michigan Health System.

Along with Philip Schoenfeld, M.D., also of the U-M Division of Gastroenterology, Chey has helped to develop the new evidence-based recommendations.

IBS is a chronic disorder of the lower intestine that causes cramping, abdominal pain, bloating, constipation and/or diarrhea that affects 10 to 15 percent of the U.S. population. The new recommendations show that "there really are things to do for these patients; it's not a hopeless situation," says Chey.

Some of the most significant evidence-based recommendations from the guideline include:

-- Most patients with typical IBS symptoms and no alarm features such as bleeding, weight loss, or a family history of colon cancer, inflammatory bowel disease or celiac sprue, do not need extensive diagnostic testing before confidently diagnosing IBS.

-- IBS patients with diarrhea or a mixture of diarrhea and constipation should be screened with blood tests for celiac disease, a condition in which one cannot tolerate the gluten protein found in wheat and other grains.

-- When patients with IBS and diarrhea undergo colonoscopy, biopsies should be obtained to rule out a rare disease called microscopic colitis.

-- The use of anti-depressants, tricyclic agents and selective serotonin reuptake inhibitors, can be helpful for some patients with IBS.

"There is a stronger recommendation that tricyclic antidepressants, used in low doses before people go to sleep at night, are an effective medicine for irritable bowel syndrome," says Schoenfeld, associate professor of internal medicine at the U-M Medical School. The agents in these antidepressants can reduce bloating and discomfort by altering brain-gut signaling about motility and distention. He adds that constipation, a side effect of tricyclic antidepressants, is actually beneficial to many people in this population.

-- The drug lubiprostone, a chloride channel activator, benefits a subset of women with IBS and constipation.

-- Evidence suggests that a specific probiotic called Bifidobacter infantis offers benefit to some patients with IBS and diarrhea.

-- The non-absorbable antibiotic called rifaximin has been found to be of benefit for selected patients with IBS, in particular those with bloating and diarrhea.

-- For women with more severe IBS and diarrhea who have not responded to standard therapies, alosetron, a drug which alters an important neurotransmitter called serotonin, can be considered.

IBS usually begins in young adulthood, and women are twice as likely as men to be diagnosed with IBS in the United States. Despite intensive research, the precise cause of IBS is not clear. Suggested contributors to IBS include abnormal contractile activity of the intestines and colon, altered sensation within the gastrointestinal tract, exaggerated reactions to stress or anxiety, and/or problems arising from the interaction between the bacteria and immune system within the intestines and colon.

Treatments are often combined to reduce the pain and bowel-related symptoms of IBS, and it may be necessary to try more than one combination to find the one that is most helpful, Chey and Schoenfeld note.

Before newer therapies and medications were available, much of the effort to treat IBS symptoms focused on lifestyle, diet and reduction of stress. Some dietary changes that many patients have found helpful:

-- Avoid or limit the amount of gas-producing foods such as beans, onions, broccoli, cabbage or any other foods that will commonly aggravate IBS symptoms.

-- Try to slow down when you eat and avoid overeating.

-- Avoid carbonated drinks. These can introduce gas into the intestines and cause bloating or abdominal discomfort.

-- Intolerance to milk sugar, or lactose, is seen in up to 40 percent of patients with IBS. Avoiding dairy products may be helpful in reducing symptoms of IBS such as gas, bloating, cramping and diarrhea.

-- Avoid large quantities of other sugars such as fructose or sorbitol which can also worsen IBS symptoms

-- The addition of fiber in the form of psyllium can help with constipation related symptoms in IBS patients.

A structured, focused diagnostic evaluation will lead to a confident diagnosis of IBS says Chey. There are some good treatment options for people diagnosed with IBS. With effective counseling, dietary and lifestyle intervention, and use of over-the-counter and/or prescription medications, IBS can be effectively managed in the vast majority of patients, Chey notes.

For a full list of the IBS guidelines please visit http://www.nature.com/ajg/journal/v104/n1s/index.html.

University of Michigan Health System
http://www.med.umich.edu

0 comments

Scientists have uncovered vital clues about how to treat serious bowel disorders by studying the behaviour of cells in the colon.

Researchers at the University of Edinburgh believe a chemical messenger that is essential for developing a baby's gut in the womb could hold the key to new treatments for inflammatory bowel disease (IBD), a condition which affects 1 in 250 people in the UK.

The team studied a chain of chemical reactions inside colon cells, called the Hedgehog signalling pathway, which controls the way it behaves and communicates with other cells.

The researchers found that some patients with IBD inherit a defective copy of one of the important links in this chain, a gene called GLI1. This defective GLI1 is only half as active as normal. Additionally, the Hedgehog pathway itself signals at lower levels than normal when the large bowel is inflamed.

The results suggest that the GLI1 protein may calm inflammation within the healthy colon, and that this process appears to go wrong in IBD patients, causing their gut to become inflamed.

The researchers now hope to test whether strengthening this weakened protein will help to prevent or treat inflammatory bowel diseases like Crohn's disease and ulcerative colitis.

Dr Charlie Lees from the University's Institute of Genetics and Molecular Medicine, who led the study, said: "Everybody has billions of bacteria in the gut, the vast majority of which do us no harm. Our body's natural immune responses identify and eliminate harmful bacteria, whilst living in harmony with the healthy bacteria. But in people with inflammatory bowel disease, that response goes wrong and an over-active immune response against these healthy bacteria leads to chronic inflammation in the gut.

"It now seems that the Hedgehog signalling pathway, and specifically the GLI1 protein, is crucial to that response. We think it provides an important signal to certain types of immune cells in the gut wall, instructing them to adopt an anti-inflammatory state. If we can find ways to bolster these responses in people with IBD, we may be able to help prevent the painful attacks which are so devastating to patients."

0 comments

Irritations of the bowel can have genetic causes. Researchers at the Institute of Human Genetics at Heidelberg University Hospital have discovered this correlation. The causes of what is known as irritable bowel syndrome (IBS), one of the most common disorders of the gastrointestinal tract, are considered unclear - making diagnosis and treatment extremely difficult. The results from Heidelberg, which were published in the prestigious journal Human Molecular Genetics, improve the outlook for an effective medication against a disease that is frequently played down as a functional disorder.

In Germany, approximately five million people are affected by IBS, women about twice as often as men. But only around 20 percent of these people even consult a physician. Many patients suffer from constipation, others from severe diarrhea, or a combination of both. The illness affects the general condition and quality of life of these patients and often lasts for months or even years.

Modified receptors lead to overstimulation of the bowel

Serotonin plays an important role in the complex processes in the digestive tract - just as it affects sleep, mood, and blood pressure. Various types of receptors are located in the intestine, to which serotonin attaches according to the lock and key principle and thus transmits cellular signals.

"We have determined that patients who suffer from irritable bowel syndrome with diarrhea show a higher frequency of certain mutations ", ex-plains Dr. Beate Niesler, who investigates the genetic causes of complex diseases with her team in the Department of Human Molecular Genetics (Director: Prof. Gudrun Rappold) at the Heidelberg Institute of Human Genetics. These mutations appear to cause changes in the composition or number of receptors on the cell surface. "The signal transduction in the digestive tract may be disturbed and this may lead to overstimulation of the intestine. Resulting disturbances in fluid balance could explain the occurrence of diarrhea", says Johannes Kapeller, a PhD student in the team.

Medication blocks serotonin receptors

The serotonin receptor blocker Alosetron is only approved in the US where it is effectively used in the treatment of women suffering from diarrhea-predominant IBS, but can only be prescribed with strict limitations due to its side effects. Alosetron inhibits the serotonin receptors in the intestinal tract and thus slows the movement of the bowels.

"Currently, patients with irritable bowel syndrome are treated on a trial and error basis", explains Dr. Beate Niesler. The Heidelberg data could contribute to development and prescription of specific medications for certain genetic mutations in patients.

Correlation with depression and pain

Research of the serotonin system shows interesting correlations serotonin receptors are located on neural transduction pathways involved in pain perception and influence them - which could explain why patients with irritable bowel syndrome often complain of severe pain although no pathological changes such as infections or tumors are present. It has also been noted that persons with modified receptors suffer more frequently from depression.

0 comments

A new study led by Spanish researchers has revealed that exposure to certain substances may increase the risk of cancer of the oesophagus. The hotel and restaurant trades, animal handling, mining and carpentry are some of the professions posing the highest risk.

Jesús Vioque, a researcher at the Miguel Hernández University in Alicante, is leading a cases and controls study looking into the relationship between occupations and three types of cancer oesophageal, pancreatic and stomach. The article showing the link between certain professions and the risk of suffering cancer of the oesophagus is the first to have been published.

The study, which appears in the latest edition of the journal Occupational and Environmental Medicine, analyses the two principle types of cancer of the oesophagus, which account for more than 90% of all cases squamous cell cancer (70 - 75%) and adenocarcinoma (15-20%).

"The two major risk factors for this cancer are alcohol and tobacco, but there is an additional number (around 4%-5%) of cases associated with certain occupations," Vioque tells SINC.

The research study, which was carried out in nine hospitals in Valencia and Alicante, involved analysing the cases of 185 men with recently-diagnosed cancer of the oesophagus (147 squamous cell cancer, 38 adenocarcinoma) and 285 healthy controls. All those who took part in the study filled in a questionnaire about their diet, profession and lifestyle. The results were adjusted to take into account factors such as age, educational level and alcohol and tobacco consumption.

For the squamous cell variety, a significant increase in risk was detected among those who worked in the hotel and restaurant trade, mining (stone cutters) and wood-working workshops. With the adenocarcinoma type, the risk rose among those working as carpenters or animal handlers. An increase was also detected among workers involved in construction and electricity, "although these were based upon a very small number of cases".

The study revealed a significant risk of squamous cell cancer resulting from exposure to ionising radiation, and for adenocarcinoma from serious exposure to volatile sulphur and lead compounds. Exposure to other substances such as asbestos could also triple the overall risk of oesophageal cancer, depending upon the level of exposure.

"We are not suggesting that people should give up their jobs, but if they are working in a high-risk profession they should adopt all suitable protection measures (goggles, masks or special machines). This is about trying to educate these workers in order to reduce their alcohol and tobacco consumption, but also to ensure they make use of all appropriate safety measures," says Vioque.

Figures in Spain

Oesophageal cancer represents between 1% and 2% of all cancers. It is the fourth most common tumour of the digestive tract, behind colon, rectal and stomach cancer. It is more common among men than women, and it tends to appear between the ages of 55 and 70, with low numbers of cases among people aged under 40. According to data from the Spanish Society of Medical Oncology (SEOM), Spain has a medium level of incidence of this cancer (approximately 8 men per 100,000 and 1 woman per 100,000) in comparison with the rest of Europe.

Spain reports an annual incidence of 1,500 men and 250 women with oesophageal cancer, with the disease appearing more frequently in the north than in the rest of the country (Basque Country, Asturias and Navarre).

Plataforma SINC
http://www.plataformasinc.es

0 comments

An analysis of previous studies indicates that smoking is significantly associated with an increased risk for colorectal cancer and death, according to an article in the December 17 issue of JAMA.

Although tobacco was responsible for approximately 5.4 million deaths in 2005, there are still an estimated 1.3 billion smokers in the world. While a number of cancers are attributable to smoking, the link between cigarette smoking and colorectal cancer (CRC) has been inconsistent among studies. "Because smoking can potentially be controlled by individual and population-related measures, detecting a link between CRC and smoking could help reduce the burden of the world's third most common tumor, which currently causes more than 500,000 annual deaths worldwide. In the United States alone, an estimate of approximately 50,000 deaths from CRC would have occurred in 2008," the authors write.

Edoardo Botteri, M.Sc., of the European Institute of Oncology, Milan, Italy, and colleagues conducted a meta-analysis to review and summarize published data examining the link between smoking and CRC incidence and death.

The researchers identified 106 observational studies, and the meta-analysis was based on a total of nearly 40,000 new cases of CRC. For the analysis on incidence, smoking was associated with an 18 percent increased risk of CRC. The researchers also found a statistically significant dose-relationship with an increasing number of pack-years (number of packs of cigarettes smoked/day, multiplied by years of consumption) and cigarettes per day. However, the association was statistically significant only after 30 years of smoking.

Seventeen studies were included in the analysis of mortality, which indicated that smokers have a 25 percent increased risk of dying from CRC than people who have never smoked. There also was an increase in risk of CRC death with increasing number of cigarettes per day smoked and for longer duration of smoking. For both incidence and death, the association was stronger for cancer of the rectum than of the colon.

"Smoking has not been considered so far in the stratification of individuals for CRC screening. However, several studies reported that CRC occurs earlier in smokers, particularly in those with heavy tobacco consumption, and our previous and present findings provide strong evidence of the detrimental effect of cigarette smoking on the development of adenomatous [benign tumor] polyps and CRC. We believe that smoking represents an important factor to consider when deciding on the age at which CRC screening should begin, either by lowering the age in smokers or increasing the age in non-smokers," the authors write.

JAMA. 2008;300[23]:2765-2778.

Journal of the American Medical Association (JAMA)